Physician profile
Carmen Coe
NPI 1942320593
$9,002.67
in general payments reported to CMS, 2019-2025
34 companies · $2,188 in 2025
The $2,188 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $1,215 · 2023: $3,235 · 2024: $1,887 · 2025: $2,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,243 · Consulting Fee: $950 · Travel and Lodging: $876 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,243.42 |
| Consulting Fee | $950.00 |
| Travel and Lodging | $876.42 |
| Education | $239.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,709.61 | 2021-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,391.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| United Therapeutics Corporation | $652.59 | 2021-2025 | Tyvaso, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $600.00 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $561.37 | 2021-2025 | Uptravi, Opsumit |
| Insmed, INC. | $559.32 | 2021-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $541.45 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.11 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $346.48 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $274.71 | 2024-2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $251.65 | 2021-2025 | Fasenra, Breztri, Symbicort |
| Takeda Pharmaceuticals U.S.A., INC. | $184.02 | 2021-2025 | Glassia |
| Inogen, INC. | $171.35 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Astellas Pharma US INC | $155.51 | 2023 | Cresemba |
| Zoll Respicardia, INC. | $142.47 | 2024-2025 | Remede System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $134.23 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $117.30 | 2021-2023 | Velphoro |
| Mylan Specialty L.P. | $106.71 | 2022-2024 | Yupelri |
| Amgen INC. | $95.88 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $78.63 | 2022-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $66.23 | 2025 | Dupixent |
| Abbott Laboratories | $46.76 | 2025 | Cardiomems |
| Viatris Specialty LLC | $43.72 | 2025 | Yupelri |
| Grifols USA, LLC | $42.23 | 2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $39.25 | 2021-2025 | Winrevair |
| Baxter Healthcare | $38.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.53 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $31.51 | 2023 | Quviviq |
| Philips North America LLC | $30.55 | 2022-2023 | |
| Lilly USA, LLC | $29.09 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $27.02 | 2023 | Sunosi |
| Janssen Pharmaceuticals, INC | $21.84 | 2023 | Xarelto |
| Verona Pharma, INC. | $14.07 | 2025 | Ohtuvayre |
| Electromed, INC. | $13.43 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.